VMD:NASDAQViemed Healthcare, Inc. Analysis

Viemed Healthcare (VMD) is trading at $8.94, well below its DCF fair value of $26.48, implying roughly a 45% upside. The stock sits above its 20‑day ($9.57) and 50‑day ($9.39) moving averages and the 200‑day average ($7.65), signaling a bullish price trend, while the MACD line is negative and the histogram is contracting, suggesting short‑term momentum weakness. RSI at 43 indicates the shares are not yet oversold, and volume is trending higher, though the 30‑day volatility of ~56% points to sizable price swings.
Fundamentally, VMD posted a robust 27.5% revenue growth YoY, with a gross margin of 57.6% and positive free cash flow of $27.9 M, while maintaining a modest debt‑to‑equity of 8.5. The company earned $0.06 EPS in Q1, missing consensus estimates, but management raised full‑year guidance and highlighted growth in sleep and maternal therapy segments. With no dividend and a “strong buy” consensus from analysts, the stock appears significantly undervalued relative to its growth profile and sector peers.